CA2211621A1 - Methodes et compositions de regulation de l'expression de cd28 - Google Patents

Methodes et compositions de regulation de l'expression de cd28

Info

Publication number
CA2211621A1
CA2211621A1 CA002211621A CA2211621A CA2211621A1 CA 2211621 A1 CA2211621 A1 CA 2211621A1 CA 002211621 A CA002211621 A CA 002211621A CA 2211621 A CA2211621 A CA 2211621A CA 2211621 A1 CA2211621 A1 CA 2211621A1
Authority
CA
Canada
Prior art keywords
oligomer
cells
seq
oligomers
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002211621A
Other languages
English (en)
Inventor
Robert C. Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/529,878 external-priority patent/US5932556A/en
Application filed by Individual filed Critical Individual
Publication of CA2211621A1 publication Critical patent/CA2211621A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des oligomères capables de réduire l'expression du gène CD28 dans un lymphocyte T. Outre des séquences spécifiques, l'invention concerne une classe d'oligomères comprenant au moins deux séquences de GGGG séparées par 3 à 5 bases. Les cibles sont, entre autres, le gène CD28, les régions 5' non traduites et le codon d'initiation et leurs produits de transcription respectifs. Les méthodes englobent l'utilisation d'oligomères pour modérer les effets pathogènes sur le système immunitaire dans des maladies induites par le système immunitaire, dont la réaction du greffon contre l'hôte, le choc septique, les maladies virales, le psoriasis, le diabète sucré (insulino-dépendant) du Type I, la thyroïdite, la sarcoïdose, la sclérose en plaques, l'uvïte auto-immune, la polyarthrite rhumatoïde, le lupus érythémateux aigu dissimulé et l'affection abdominale inflammatoire.
CA002211621A 1995-02-09 1996-02-05 Methodes et compositions de regulation de l'expression de cd28 Abandoned CA2211621A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38704195A 1995-02-09 1995-02-09
US08/387,041 1995-02-09
US08/529,878 1995-09-17
US08/529,878 US5932556A (en) 1995-09-17 1995-09-17 Methods and compositions for regulation of CD28 expression

Publications (1)

Publication Number Publication Date
CA2211621A1 true CA2211621A1 (fr) 1996-08-15

Family

ID=27011718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002211621A Abandoned CA2211621A1 (fr) 1995-02-09 1996-02-05 Methodes et compositions de regulation de l'expression de cd28

Country Status (7)

Country Link
JP (1) JP2002515013A (fr)
KR (1) KR100258826B1 (fr)
CN (1) CN1181021A (fr)
AU (1) AU703139B2 (fr)
CA (1) CA2211621A1 (fr)
CZ (1) CZ250097A3 (fr)
SK (1) SK108697A3 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561978A1 (fr) * 2004-03-31 2005-10-13 Lions Eye Institute Limited Molecules therapeutiques pour moduler la stabilite de transcrits du vegf
DK2480669T3 (en) * 2009-09-25 2018-02-12 Curna Inc TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) * 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US5254638A (en) * 1991-03-25 1993-10-19 The Reagents Of The University Of California Composite materials of interpenetrating inorganic and organic polymer networks
GB9310842D0 (en) * 1993-05-26 1993-07-14 Imperial College Gene identification

Also Published As

Publication number Publication date
AU703139B2 (en) 1999-03-18
CZ250097A3 (cs) 1998-01-14
KR19980702101A (ko) 1998-07-15
JP2002515013A (ja) 2002-05-21
SK108697A3 (en) 1998-04-08
AU5295896A (en) 1996-08-27
CN1181021A (zh) 1998-05-06
MX9705963A (es) 1998-08-30
KR100258826B1 (ko) 2000-07-01

Similar Documents

Publication Publication Date Title
US5932556A (en) Methods and compositions for regulation of CD28 expression
US6994959B1 (en) G-rich oligo aptamers and methods of modulating an immune response
AU712228B2 (en) Compositions and methods for antisense inhibition of protein translation
EP0677056B1 (fr) Alkylphosphonates et alkylphosphonothioates d'oligonucleotides
US7928083B2 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
EP0590090A1 (fr) INHIBITION SELECTIVE DE LA PROLIFERATION DES CELLULES LEUCEMIQUES PAR DES OLIGONUCLEOTIDES ANTI-CODANTS $i(BCR-ABL)
US6429308B1 (en) HIV infection inhibitors
CA2273203A1 (fr) Inhibition antisens de molecules d'adhesion humaines
EP1008649A2 (fr) Oligonuclétides antisense pour le traitement des effets immunosuppresseurs du TGF-beta2
WO1996024380A9 (fr) Methodes et compositions de regulation de l'expression de cd28
WO1996024380A1 (fr) Methodes et compositions de regulation de l'expression de cd28
AU703139B2 (en) Methods and compositions for regulation of CD28 expression
WO2001074136A2 (fr) Polynucleotides inhibiteurs de la telomerase
CA2223109A1 (fr) Utilisation d'oligonucleotides antisens complementaires de l'arnm du recepteur de l'interleukine-6 pour inhiber la proliferation cellulaire
MXPA97005963A (en) Methods and compositions for the regulation of the expression of c
Yang et al. Analysis of the complex genomic structure of Bcl-x and its relationship to Bcl-xγ expression after CD28-dependent costimulation
JP3476509B2 (ja) 熱力学的に安定なループを有するヘアピン型リボザイム
MXPA99005880A (en) G-rich oligo aptamers and methods of modulating an immune response
JPH11285391A (ja) 抗ｈｉｖ剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued